Advertisement

Clinical Pharmacokinetics

, Volume 27, Issue 5, pp 331–336 | Cite as

Future of Prodrugs in Antiviral Therapy

  • Tetsuya Hasegawa
  • Takeo Kawaguchi
Leading Article

Keywords

Adis International Limited Zidovudine Didanosine Zalcitabine Pivalate 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Wong-Stall F. The human immunodeficiency virus genome:structure and function. In: Lopez C, editor. Immunobiology and pathogenesis of persistent virus infections. Washington DC: American Society of Microbiology, 1988: 171–9Google Scholar
  2. 2.
    Tisdale M, Larder BA, Lowe DM, et al. Structural characterization of HIV reverse transcriptase: a target for the design of specific virus inhibitors. J Antimicrob Chemother 1989; 23 Suppl. A: 47–54PubMedGoogle Scholar
  3. 3.
    Kraus G, Behr E, Baier M. Simian immunodeficiency virus reverse transcriptase-purification and partial characterization. Eur J Biochem 1990; 192: 207–13PubMedCrossRefGoogle Scholar
  4. 4.
    Waqar MA, Evans MJ, Manly KF, et al. Effect of 2′,3′-dideoxynucleosides on mammalian cells and viruses. J Cell Physiol 1984; 121: 402–8PubMedCrossRefGoogle Scholar
  5. 5.
    Mitsuya H, Broder S. Inhibition of the in vitro infectivity and cytopathic effect of human T-lymphotrophic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV) by 2′,3′dideoxynucleosides. Proc Natl Acad Sci USA 1986; 83: 1911–5PubMedCrossRefGoogle Scholar
  6. 6.
    Mitsuya H, Broder S. Strategies for antiviral therapy in AIDS. Nature 1987; 325: 773–8PubMedCrossRefGoogle Scholar
  7. 7.
    Starnes MC, Cheng YC. Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem 1987; 262: 988–91PubMedGoogle Scholar
  8. 8.
    Hao Z, Cooney DA, Hartan NR, et al. Factors determining the activity of 2′,3′-dideoxynucleosides in suppressing human immunodeficiency virus in vitro. Mol Pharmacol 1988; 34: 431–5PubMedGoogle Scholar
  9. 9.
    Yarchoan R, Mitsuya H, Myers CE, et al. Clinical pharmacology of 3′-azido-2′,3′-dideoxythymidine (zidovudine) and related dideoxynucleosides. N Engl J Med 1989; 321: 726–38PubMedCrossRefGoogle Scholar
  10. 10.
    Resetar A, Spector T. Glucuronidation of 3′-azido-3′-deoxythymidine: human and rat enzyme specificity. Biochem Pharmacol 1989; 38: 1389–93PubMedCrossRefGoogle Scholar
  11. 11.
    Russell JW, Klunk LJ. Comparative pharmacokinetics of new anti-HIV agents: 2′,3′-dideoxyadenosine and 2′,3′-dideoxyinosine. Biochem Pharmacol 1989; 38: 1385–8PubMedCrossRefGoogle Scholar
  12. 12.
    Stella V. Pro-drugs: an overview and definition. In: Higuchi T, Stella V, editors. Prodrugs as novel drug delivery systems. Washington DC: American Chemical Society, 1975: 1–115CrossRefGoogle Scholar
  13. 13.
    Kawaguchi T, Ishikawa K, Seki T, et al. Ester prodrugs of zidovudine. J Pharm Sci 1990; 79: 531–3PubMedCrossRefGoogle Scholar
  14. 14.
    Kawaguchi T, Endoh T, Seki T, et al. Plasma concentrations of zidovudine in rats via oral administration of its ester prodrugs. J Pharm Sci 1991; 80: 404–5PubMedCrossRefGoogle Scholar
  15. 15.
    Hasegawa T, Seki T, Juni K, et al. Prodrugs of 2′,3′-didehydro-3′-deoxythymidine. J Pharm Sci 1993; 82: 1232–6PubMedCrossRefGoogle Scholar
  16. 16.
    Anderson BD, Wygant MB, Xiang TX, et al. Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleosides: potent anti-AIDs agents. Int J Pharm 1988; 45: 27–37CrossRefGoogle Scholar
  17. 17.
    Kawaguchi T, Hasegawa T, Seki T, et al. Prodrugs of 2′,3′-dideoxyinosine (DDI): improved oral bioavailability via hydrophobic esters. Chem Pharm Bull 1992; 40: 1338–40PubMedCrossRefGoogle Scholar
  18. 18.
    Lupia RH, Ferencz N, Lertora JJL, et al. Comparative pharmacokinetics of two prodrugs of zidovudine in rabbits: enhanced levels of zidovudine in brain tissue. Antimicrob Agents Chemother 1993; 37: 818–24PubMedCrossRefGoogle Scholar
  19. 19.
    Morgan ME, Chi SC, Murakami K, et al. Central nervous system targeting of 2′,3′-dideoxyinosine via adenosine deaminase-activated 6-halo-dideoxypurine prodrugs. Antimicrob Agents Chemother 1992; 36: 2156–65PubMedCrossRefGoogle Scholar
  20. 20.
    Gogu SR, Aggarwal SK, Rangan SRS, et al. A pro-drug of zidovudine with enhanced efficacy against human immunodeficiency virus. Biochem Biophys Res Commun 1989; 160: 656–61PubMedCrossRefGoogle Scholar
  21. 21.
    Hostetler KY, Stuhmiller LM, Lenting HBM, et al. Synthesis and antiretroviral activity of phospholipid analogs of azidothymidine and other antiviral nucleosides. J Biol Chem 1990; 265: 6112–7PubMedGoogle Scholar
  22. 22.
    Shao Z, Park GB, Krishnamooathy R, et al. The physicochemical properties, plasma enzymatic hydrolysis, and nasal absorption of acyclovir and its 2′-ester prodrugs. Pharm Res 1994; 11: 237–47PubMedCrossRefGoogle Scholar
  23. 23.
    Ghosh MK, Mitra AK. Brain parenchymal metabolism of 5-iodo-2′deoxyuridine and 5′-ester prodrugs. Pharm Res 1992; 9: 1048–52PubMedCrossRefGoogle Scholar

Copyright information

© Adis international Limited 1994

Authors and Affiliations

  • Tetsuya Hasegawa
    • 1
  • Takeo Kawaguchi
    • 1
  1. 1.Faculty of Pharmaceutical SciencesJosai University SakadoSakado, SaitamaJapan

Personalised recommendations